logo

For the Inventor, By the Inventor

Brentwood, TN, United States of America

Colleen M Niswender

This inventor holds 20 USPTO granted patents and 7 published patent applications, primarily in Neurological Treatments. Top assignee: Vanderbilt University. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Colleen M Niswender. Retrieved from https://idiyas.com/inventor/colleen-m-niswender

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 85.0

Average Co-Inventor Count = 7.0

ph-index = 9

Forward Citations = 144(Granted Patents)


Company Filing History:

goldMedal20 out of 1,221 
 
Vanderbilt University
 patents

Years Active: 2011-2025

Loading Chart...
Areas of Expertise:
mGluR4 Potentiators
Allosteric Modulators
Indazole Compounds
Neurological Dysfunction
Benzothiazole
Isoquinoline
Heterocyclic Sulfones
Pyrazolopyridine
Benzamide
Dioxopiperidines
Pyridine Quinoline
Bicyclic Compounds
20 patents (USPTO):Explore Patents
1. 12291521 - Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2025-05-06),
2. 11427573 - Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2022-08-30),
3. 11319304 - Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2022-05-03),
4. 10526323 - Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2020-01-07),
5. 10508105 - Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2019-12-17),
6. 10227343 - Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2019-03-12),
7. 10221172 - Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2019-03-05),
8. 9980945 - Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2018-05-29),
9. 9192603 - Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2015-11-24),
10. 9180192 - mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2015-11-10),
11. 9163015 - Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2015-10-20),
12. 9108963 - Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2015-08-18),
13. 8916584 - Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2014-12-23),
14. 8912336 - Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2014-12-16),
15. 8853392 - Benzamide mGluR5 positive allosteric modulators and methods of making and using same (2014-10-07),

Title: Colleen M. Niswender: Pioneering Innovations in Neurological Treatments

Introduction: Colleen M. Niswender, based in Brentwood, Tennessee, is a distinguished inventor in the field of pharmaceuticals with a focus on neurological dysfunction. With a remarkable portfolio of 19 patents, her work is essential in advancing therapeutic options for conditions related to glutamate dysfunction.

Latest Patents: Among her latest patents are groundbreaking contributions to medical science. Her inventions include indazole compounds that serve as allosteric potentiators for the metabotropic glutamate receptor subtype 4 (mGluR4). These compounds have significant potential for treating neurological and psychiatric disorders. Similarly, her patent on pyridine quinoline compounds as mGluR4 allosteric potentiators offers synthetic methods and pharmaceutical compositions that aim to improve treatments for diseases associated with glutamate dysfunction.

Career Highlights: Colleen M. Niswender's career is marked by her innovative research at Vanderbilt University. Her continuous pursuit of knowledge and application in pharmaceutical sciences reflects her commitment to developing effective treatments for complex neurological conditions. The insights gained from her research are invaluable, making a tangible impact on the field.

Collaborations: Throughout her career, Colleen has collaborated with other esteemed researchers, including P. Jeffrey Conn and Craig William Lindsley. These partnerships have led to significant advancements in understanding and addressing neurological disorders, highlighting the importance of teamwork in the scientific community.

Conclusion: Colleen M. Niswender continues to be a pivotal figure in pharmaceutical innovation, particularly in her work related to neurological dysfunction. Her extensive patent portfolio signifies a deep commitment to enhancing therapeutic options for patients suffering from various psychological and neurological disorders. As her research progresses, the scientific community eagerly anticipates the future implications of her groundbreaking inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…